Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Rz9456: Potential hematopoietic stem cell therapy for AIDS

July 26, 1996

Cyanovirin-N selected for high priority development by the National Cancer Institute

July 26, 1996

CHAM3 induces clinical and biological improvement in HIV patients

July 26, 1996

ZY-1 demonstrates therapeutic promise in HIV patients

July 26, 1996

TAR-PAK-140: University of Alberta's anti-HIV vector

July 26, 1996

Mulsal N shows significant CD4 cell count increases in trial

July 26, 1996

Virulizin enters phase I/II for drug-resistant HIV-related Kaposi's sarcoma

July 26, 1996

Columbia Laboratories' SPC3 undergoes phase I/II trials

July 26, 1996

Allophenylnorstatine HIV protease inhibitors described

July 26, 1996

Sequus licenses liposome-CD4 technology

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...